Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New study supports diabetes-infection link
The study, the biggest of its kind, analyzed information from a register of over 4,000 people aged up to 29 years diagnosed with type 1 diabetes over a
The study, the biggest of its kind, analyzed information from a register of over 4,000 people aged up to 29 years diagnosed with type 1 diabetes over a
Metabolic syndrome is a group of conditions that increase the risk for heart disease, stroke and diabetes. The conditions include high blood pressure, excess body fat around the
The Rochester study is the first to compare gabapentin (marketed as Neurontin by Pfizer) and estrogen head-to-head against a placebo. Although it showed a substantial placebo effect similar
Under the agreement, Janssen will have exclusive rights in Europe, South America, the Middle East, Africa and Australia, and Vertex will retain exclusive commercial rights to VX-950 in
The advert in question appeared in an edition of Newsweek and features a forty-something African-American couple. Michael Weinstein, president of the AIDS Healthcare Foundation (AHF), said the ad
The new indication approval is for Revlimid (lenalidomide), in combination with dexamethasone, as a treatment for patients with multiple myeloma who have received at least one prior therapy.
The approval covers cefprozil for oral suspension in 125mg/5mL and 250mg/5mL dosages. Cefprozil suspension is indicated for the treatment of patients with mild to moderate infections caused by
New River has filed the investigational new drug (IND) application for NRP409, a triiodothyronine (T3) hormone, as a treatment for patients with primary hypothyroidism. The company hopes that
Ketek’s US prescribing information has been revised after discussion with the FDA to provide healthcare professionals and patients with updated information about adverse events reported in connection with
Beginning with Teva, the Israeli generics giant has received final FDA approval for its abbreviated new drug application (ANDA) to market a generic version of Pfizer’s Zoloft (sertraline)